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ABSTRACT  
Objective: To determine the feasibility of conducting a randomised controlled trial of a 
specialist physiotherapy intervention for functional motor symptoms (FMS).  
Methods: A randomised feasibility study was conducted recruiting patients with a clinically 
established diagnosis of FMS from a tertiary neurology clinic in London, UK. Participants were 
randomised to the intervention or a treatment as usual control. Measures of feasibility and 
clinical outcome were collected and assessed at 6 months.  
Results: Sixty individuals were recruited over a nine month period. Three withdrew, leaving 
29 intervention and 28 controls participants in the final analysis. Thirty-two per cent of 
patients with FMS met the inclusion criteria, of which 90% enrolled. Acceptability of the 
intervention was high and there were no adverse events. At six months, 72% of the 
intervention group rated their symptoms as improved, compared to 18% in the control 
group. There was a moderate to large treatment effect across a range of outcomes, including 
three of eight SF36 domains (d=0.46–0.79). The SF36 Physical Function was found to be a 
suitable primary outcome measure for a future trial; adjusted mean difference 19.8 (95% CI 
10.2–29.5). The additional quality adjusted life years (QALY) with intervention was 0.08 (95% 
CI 0.03–0.13), the mean incremental cost per QALY gained was £12,087. 
Conclusions: This feasibility study demonstrated high rates of recruitment, retention, and 
acceptability. Clinical effect size was moderate to large with high probability of being cost 
effective. A randomised controlled trial is needed. 
Funding: NIHR/HEE CDR Fellowship. 
ClinicalTrials.gov registration NCT02275000 
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INTRODUCTION 
Functional neurological disorder (conversion disorder), accounts for 15% of all new patients 
seen in general neurology clinics.[1,2] Approximately 10-50% present with functional motor 
symptoms (FMS), typically weakness, tremor and gait disorder.[1,2] These patients 
experience disability and distress equivalent to those suffering from degenerative 
neurological disease.[3] Prognosis is poor; at an average of seven years follow up, 40% have 
similar or more severe symptoms, and the majority remain symptomatic.[4]  
Despite the prevalence and impact of symptoms, there is limited evidence regarding 
effective treatment. Psychological therapy is traditionally proposed as the treatment 
modality of choice, but physically based interventions have emerged as a promising 
treatment. A randomised delayed-start study of three weeks inpatient physical rehabilitation 
“with a cognitive behavioural framework”, found an improvement in measures of physical 
functioning  which were maintained at 12 months follow up.[5] A systematic review of 
physiotherapy for FMS (including 564 subjects) supports the view that physiotherapy 
outcomes are promising and warrant further investigation with a randomised controlled trial 
(RCT).[6] The interventions employed in this literature differ from physiotherapy for typical 
neurological disease which we have described in consensus recommendations for 
physiotherapy practice.[7] This approach has been tested in two cohort studies which report 
improvement in physical functioning.[8,9] 
We aimed to determine the feasibility of an RCT of specialist physiotherapy for FMS. Specific 
aims were to test acceptability and feasibility of a treatment protocol based on consensus 
recommendations; to test the utility of a range of outcome measures; and to collect outcome 
data to determine the sample size required for a large scale trial.  
METHODS 
Study Design and Setting 
We conducted a two parallel arm, randomised feasibility study of a five day specialist 
physiotherapy-led intervention versus a treatment as usual control for patients with FMS. 
This study took place at the National Hospital for Neurology and Neurosurgery, London, UK. 
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Approval was obtained from the National Research Ethics Service Committee London – City 
Road & Hampstead (14/LO/0572). All participants gave written informed consent. A trial 
steering committee oversaw the conduct of the trial. The trial was registered at 
ClinicalTrials.gov (NCT02275000). 
Participants 
Sixty participants were recruited from new patients attending an outpatient neurology clinic 
specialising in movement disorders and FMS.  Inclusion criteria were: a clinically established 
diagnosis of FMS according to Fahn-Williams criteria;[10] age 18 years or older; completed 
diagnostic investigations; acceptance of the diagnosis on the balance of probability (i.e. we 
did not exclude patients who continued to express some doubt over the diagnosis); FMS 
duration of at least six months; symptoms severe enough to cause distress or impairment in 
social or occupational functioning. Exclusion criteria were: unable to understand English; pain 
or fatigue that we judged to be the primary cause of the patient’s disability; prominent 
dissociative seizures for which the patient required assistance to manage; clinically evident 
anxiety or depression that we felt required assessment before starting physiotherapy 
treatment; high level of disability that prevented participation in an outpatient/day hospital 
environment; and unable to attend five consecutive days of treatment.  
Prior to enrolment, all participants attended a consultation with the study neurologist (MJE) 
where the diagnosis of FMS was made. Each patient received a standard comprehensive 
explanation of the diagnosis.[11] The patient was also referred to online sources of 
information (www.neurosymptoms.org, www.FNDHope.org). Patients meeting the selection 
criteria were provided with written information about the trial and invited to return for 
consent and baseline assessment.  
Randomisation and masking 
Eligible consenting participants were randomly allocated (1:1) to the intervention or control 
group using a secure online randomisation application (Sealed Envelope, London, UK). The 
randomisation procedure was completed after baseline assessment by the study lead 
physiotherapist (GN) or independent research physiotherapist (MD). Participants were 
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immediately informed of their treatment allocation. Both participants and clinicians were 
unmasked to treatment allocation. 
Procedures  
The intervention was a protocolised five day programme, delivered by a 
neurophysiotherapist (KH) who had undertaken additional specific training (from GN). 
Participants were admitted to a day hospital for five consecutive days, within four weeks of 
baseline assessment. The first session was a joint consultation with the neurologist and 
physiotherapist where diagnostic information was reviewed and the aims of the programme 
discussed. These were explained as retaining movement and learning how to manage 
symptoms in the longer term. The programme consisted of eight sessions over five 
consecutive days, each lasting 45-90 minutes. Each session included education, movement 
retraining, and development of a management plan. Education was centred on a physical 
biased aetiological model for functional motor symptoms.[8] The physiotherapist and 
participant collaboratively devised a symptom formulation taking into account triggering 
events, comorbidity, psychological factors, self-focussed attention, and unhelpful 
reinforcement of symptomatic movement patterns. Movement retraining aimed to restore 
normal movement during problematic activities by redirecting the focus of motor 
attention.[7] The participant and physiotherapist made notes in a workbook, documenting 
the individualised symptom formulation, information about FMS, specific symptom 
management strategies, daily reflections, a personal self management plan and what to do in 
case of symptom exacerbation.  
For controls, a referral was made to the participant’s local neurophysiotherapy service. The 
referral letter contained information about the diagnosis, specific treatment goals, and 
welcomed contact for further information regarding the diagnosis or treatment advice. No 
attempt was made to standardise treatment provided. Input received was recorded, based 
on patient report.  
Participants were re-assessed at four weeks and six months by MD. For the intervention 
group, the four week assessment coincided with the final day of treatment.  
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Outcome Measures 
Measures of feasibility were: recruitment rate; retention; intervention fidelity; and 
acceptability of the intervention. Safety was assessed by participant reported adverse events. 
We did not specify a primary clinical outcome measure as the primary aim of this study 
related to feasibility. Clinical outcome measures collected were:  Short Form 36 (SF36);[12] 
Hospital Anxiety and Depression Scale (HADS);[13] EQ-5D-5L;[14] Work and Social 
Adjustment Scale (WSAS);[15] 5-point patient rated Clinical Global Impression Scale 
(CGI);[16,17] Disabilities of the Arm Shoulder and Hand (DASH);[18] Functional Mobility 
Scale;[19] Berg Balance Scale;[20] Brief Illness Perception Questionnaire (B-IPQ);[21] and 10 
metre timed walk. The CGI was collapsed into two groups: good outcome (ratings of much 
improved and improved) and poor outcome (ratings of no change, worse or much worse). 
We collected additional data on the economic impact of symptoms as well as qualitative data 
related to the intervention, which will be reported elsewhere. Participants in the intervention 
group completed a feedback form to assess acceptability of the intervention.  
Statistical Analysis 
A power calculation was not performed as the primary aim of this study was to assess 
feasibility. The sample size of 60 was predetermined and considered sufficient to meet the 
objectives of collecting data on outcome measure variation, recruitment and retention. For 
continuous measures, the difference between groups was assessed using a linear regression 
model, adjusting for the baseline scores of the measure. Treatment effect was calculated 
using Cohen’s d to allow comparisons between outcome measures.[22] Incomplete cases due 
to drop out were excluded from analysis. Data were analysed using SPSS version 22. The EQ-
5D-5L utility scores[23] were converted to Quality Adjusted Life Years (QALYs) by calculating 
the area under the curve adjusting for baseline differences.[24] Physiotherapist and 
neurologist salaries, on-costs and overheads were obtained from the Personal Social Services 
Research Unit[25] and multiplied by the average contact time per patient. Other costs were 
obtained from trial costings documentation and were for the 2014/2015 financial year. The 
estimated mean cost per patient of the intervention minus the mean cost of control 
neurophysiotherapy services was divided by the difference in QALYs gained between groups 
to calculate the incremental cost-effectiveness ratio (ICER).  
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RESULTS 
The trial profile is shown in figure 1. Between Sept 8 2014, and Jun 4 2015, 210 new patients 
were screened and 143 excluded. The commonest reasons for exclusion were dominant pain 
(n=57, 27% of screened patients), clinically evident anxiety or depression requiring 
assessment (n=50, 24% of screened patients) and dominant fatigue (n=22, 10% of screened 
patients). Seven patients declined to participate and the remaining 60 were recruited and 
randomly assigned to the intervention (n=30) and control (n=30) groups. 31.9% (95% CI 25.6–
38.2) of screened patients met selection criteria. Ninety of eligible patients consented to 
participate. The number assessed at the primary endpoint was 29 for the intervention group 
and 28 for the control group. The dropout rate was 5%. One participant from the 
intervention group was unable to attend the final assessment but they agreed to complete 
questionnaires by post; their final physical assessment measures (Berg Balance Scale and 10 
metre walk time) were therefore missing. Three participants from the control group did not 
attend the interim four week assessment.  
Baseline characteristics of the participants are shown in table 1. The mean age was 43 years, 
72% were women and approximately half the participants were not working due to ill health. 
Mean FMS duration was 5.8 years (SD 7.3) and mean age of symptom onset was 37 (SD 12.0).  
Continuous clinical outcome measures for baseline and six month outcome are reported in 
table 2, (see supplementary online data for four week outcome scores). Inspection of 
baseline data suggested that the control group had generally worse scores than the 
intervention group, which were accounted for in the analysis.  
We tested the assumptions of the regression model, which were met. After adjusting for 
baseline scores, at six months the intervention group had superior scores (representing 
better health) in three domains of the SF36 (Physical Function, Physical Role, and Social 
Function);  the Berg Balance Scale, the 10 metre walk time, the Functional Mobility Scale, the 
DASH, and the composite B-IPQ score. Two outliers skewed the results of the 10 metre walk 
time, inflating the treatment effect. After removing outliers, the mean difference remained 
significant. Effect sizes were medium to large, ranging from d=0.46 to 0.79. Outcomes that 
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were not different between groups were the remaining five domains of the SF36, HADS 
anxiety and depression scores, and the WSAS.  
The CGI data are presented in table 3. At six months 72% of the intervention group reported 
a good outcome, compared to 18% in the control group. Thirty-two per cent of the control 
group felt that their symptoms had got worse from baseline to six month follow up, 
compared to 3% in the intervention group.  
The mean EQ-5D-5L utility scores at baseline, four weeks, and six months are presented in 
figure 2. Adjusting for baseline differences, the mean QALYs over six months for the 
intervention group was 0.34 (95% CI 0.31–0.37) and 0·26 (95% CI 0.22–0.30) for the control 
group with a mean gain in QALYs per patient of 0·08 (95% CI 0.03–0.13). The cost of the 
intervention was estimated to be £1200 per patient. Costs included consultant neurology 
time, physiotherapy time (NHS band 7), equipment and consumables (including intervention 
workbook and issuing less supportive splints or walking aids for some patients only), lunch 
for five days and hotel accommodation for four nights (costs are itemised in online 
supplementary data). The cost of control was on average 4.8 sessions per patient multiplied 
by the cost of 1 hour of a neurophysiotherapist Band 7 (£49) or £233 per patient. Based on 
this data, the mean incremental cost per QALY gained was £12,087. 
In the post-treatment feedback form, all participants in the intervention group reported they 
were either completely satisfied (86%) or satisfied (14%) with their treatment and they 
would be extremely likely (93%) or likely (7%) to recommend the programme to family and 
friends if they required similar treatment. The intensity of treatment was considered about 
right (38%) or very intense but manageable (48%). Treatment fidelity data is reported in 
online supplementary data and was considered satisfactory. 
All control participants but one had been seen by a community physiotherapist in the period 
from baseline to six month follow up. The number of sessions ranged from 1 to 17; the 
median number was 5 (IQR 3–7·5). The content of physiotherapy sessions (reported by 
participants) included gait retraining, stair practice, balance, nonspecific cardiovascular 
exercise, specific strengthening exercises, and stretching. Four participants were provided 
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with a walking aid or splint. One participant had fatigue management education and one 
participant was given specific strategies aimed at controlling a functional tremor.  
No serious adverse incidents were reported during the study period.  Some participants from 
the intervention group reported exacerbation of chronic pain or fatigue during, and the week 
following treatment. These resolved without the need for a new intervention. No 
participants reported deterioration of mental health associated with treatment.  
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Figure 1. Trial Profile 
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Table 1. Baseline demographic and clinical characteristics 
 INTERVENTION n=30 CONTROL n=30 OVERALL 
DEMOGRAPHIC DATA    
Age, mean (SD) 44 (13·1) 41 (13·1) 43 (13·1) 
Female sex 22 (73%) 21 (70%) 43 (72%) 
Marital status    
 Married/partner 19 (63%) 18 (60%) 37 (62%) 
 Single 11 (37%) 12 (40%) 23 (38%) 
Employment status     
 In paid work or full time study 14 (48%) 12 (40%) 26 (43%) 
 Not working due to ill health 14 (45%) 15 (50%) 29 (48%) 
 Retired 2 (7%) 3 (10%) 5 (8%) 
Education level    
 Less than 16 years 2 (7%) 1 (3%) 3 (5%) 
 Up to 16 years 8 (27%) 13 (43%) 21 (35%) 
 Up to 18 years 4 (13%) 6 (20%) 10 (17%) 
 Degree level qualification 13 (43%) 9 (30%) 22 (37%) 
 Post graduate qualification 3 (10%) 1 (3%) 4 (7%) 
CLINICAL DATA    
Symptom duration in years, mean (SD) 5·9 (8·3) 5·6 (6·2) 5·8 (7·3) 
Age at symptom onset, mean (SD) 38 (12·9) 36 (11·2) 37 (12·0) 
Primary Symptom, frequency:    
 Weakness 3 (10%) 4 (13%) 7 (12%) 
 Gait disturbance 9 (30%) 7 (23%) 16 (27%) 
 Upper limb tremor 3 (10%) 3 (10%) 6 (10%) 
 Head tremor 2 (7%) 1 (3%) 3 (5%) 
 Fixed dystonia 0 1 (3%) 1 (2%) 
 Jerks 2 (7%) 1 (3%) 3 (5%) 
 Mixed movement disorder 11 (37%) 13 (43%) 24 (40%) 
Sensory Symptoms, frequency    
 Visual disturbance 11 (37%) 12 (40%) 23 (38%) 
 Hearing difficulties 8 (27%) 6 (20%) 14 (23%) 
 Pins and needles 15 (50%) 23 (77%) 38 (63%) 
 Numbness 14 (47%) 20 (67%) 34 (57%) 
 Dizziness 15 (50%) 14 (47%) 29 (48%) 
Other Symptoms / Complaints:    
 Weakness* 20 (67%) 23 (77%) 43 (72%) 
 Headache  14 (47%) 22 (73%) 36 (60%) 
 Sleep disturbance 18 (62%) 20 (67%) 38 (63%) 
 Gastrointestinal complaints 9 (30%) 6 (20%) 15 (25%) 
 Bladder problems 9 (31%) 11 (37%) 20 (33%) 
 Speech disturbance 13 (43%) 16 (53%) 29 (48%) 
 Concentration or attention problems 23 (77%) 22 (73%) 45 (75%) 
 Dissociative seizures  6 (20%) 3 (10%) 9 (15%) 
Pain self rating None 6 (20%) 1 (3%) 7 (12%) 
 Slight to moderate 10 (34%) 14 (47%) 24 (40%) 
 Severe to extreme 13 (45%) 15 (50%) 28 (47%) 
Fatigue self rating None 2 (7%) 1 (3%) 3 (5%) 
 Slight to moderate 13 (43%) 14 (47%) 27 (45%) 
 Severe to extreme 15 (50%) 15 (50%) 30 (50%) 
Patients reporting falls 10 (33%) 19 (63%) 29 (48%) 
Previous physiotherapy 23 (77%) 23 (77%) 46 (77%) 
Previous psychological therapy 9 (31%) 10 (33%) 19 (32%) 
* Including participants who reported weakness that was in addition to their primary symptom (e.g. gait disturbance 
and subjective complaint of weakness) 
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Table 2. Continuous outcome measure scores at baseline and 6 month follow up 
 Intervention Group 
mean (SD) 
Control Group 
mean (SD) 
Regression 
coefficient for group, 
baseline as covariate 
(95% CI) 
Cohen’s 
d 
BASELINE FOLLOW 
UP 
BASELINE  FOLLOW 
UP 
SF36 Domains        
    Physical function 34·8 (23·7) 51·9 (27·2) 23·7 (19·0) 23·2 (21·3) 19·8 (10·2, 29·5) 0·70 
    Physical Role 31·7 (28·9) 47·0 (30·3) 19·4 (21·7) 26·8 (22·5) 13·0 (0·8, 25·2) 0·46 
    Bodily Pain 45·6 (33·5) 47·4 (33·1) 32·1 (25·3) 33·9 (27·4) 3·6 (-8·0, 15·3) 0·12 
    General Health 47·3 (23·9) 54·1 (28·3) 40·7 (23·4) 39·6 (22·6) 9·0 (-0·1, 18·2) 0·34 
    Vitality 32·3 (21·4) 39·2 (27·3) 26·6 (17·6) 28·3 (20·2) 6·2 (-3·6, 15·9) 0·25 
    Social Function 39·7 (33·2) 56·9 (30·2) 34·4 (29·8) 37·0 (25·1) 17·1 (5·0, 29·2) 0·58 
    Role Emotional 70·1 (29·5) 68·7 (34·5) 61·0 (32·6) 62·5 (35·4) 0·1 (-15·1, 15·4) 0·00 
    Mental Health 65·5 (21·1) 67·9 (23·8) 58·4 (23·8) 59·3 (25·2) 3·4 (-6·4, 13·2) 0·14 
Physical Summary score  33·1 (11·1) 38·7 (10·8) 28·7 (7·9) 29·5 (9·2) 5·9 (2·1, 9·7) 0·54 
Mental Summary score 45·2 (13·0) 45·9 (13·6) 42·6 (13·3) 43·3 (14·2) 0·9 (-4·9, 6·8) 0·06 
        
HADS Anxiety 6·5 (3·8) 6·9 (4·8) 7·7 (4·9) 7·9 (5·6) -0·1 (-2·1, 2·0) -0·02 
HADS Depression 5·4 (4·0) 5·2 (3·9) 8·0 (4·5) 8·4 (5·0) -1·4 (-3·2, 0·5) -0·30 
WSAS 24·7 (7·9) 20·2 (10·5) 27·6 (7·5) 26·9 (10·2) -4·2 (-8·4, 0·1) -0·39 
Berg Balance Scale 39·0 (13·8) 47·7 (13·8) 35·7 (13·2) 37·0 (14·7) 8·0 (2·9, 13·1) 0·53 
10 metre walk time * 16·8 (10·0) 9·6 (3·8) 24·6 (17·3) 19·0 (10·6) -6·7 (-10·7, -2·8) -0·72 
Functional Mobility Scale 11·7 (4·1) 14·5 (3·5) 10·0 (3·6) 10·0 (3·9) 3·4 (1·9, 5·0) 0·79 
DASH 51·8 (19·6) 39·6 (25·6) 51·2 (15·0) 48·1 (21·4) -9·1 (-17·4, -0·8) -0·38 
B-IPQ composite score 50·0 (10·8) 39·4 (16·1) 54·6 (10·6) 51·0 (13·0) -8·0 (-14·4, -1·6) 0·51 
* 2 outliers removed from the intervention group (baseline times of 197 and 182 seconds). Removing these 
outliers decreased the treatment effect by 1.4 seconds. Higher scores represent better health in the SF36, Berg 
Balance and Functional Mobility Scale. Higher scores represent worse health for HADS, Work and Social 
Adjustment, 10 metre timed walk and DASH. Abbreviations: HADS=Hospital Anxiety and Depression Scale; 
WSAS=Work and Social Adjustment Scale; DASH=Disabilities of Arm Shoulder and Hand. 
 
 
Table 3. Clinical Global Impression Scale at 6 months. We defined a good outcome as a rating 
of improved or much improved, and a poor outcome as a rating of no change, worse or much 
worse. 
 Intervention Group Control Group 
Much worse 0  3 (11%) 
Worse 1 (3%) 6 (21%) 
No change 7 (24% 14 (50%) 
Improved 11 (38%) 5 (18%) 
Much improved 10 (35%) 0  
 
Collapsed Scores 
    
Good Outcome 21 (72%) 5 (18%) 
Poor Outcome 8 (28%) 23 (82%) 
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Figure 2. Mean EQ-5D-5L utility scores at baseline, four weeks and six months for the 
intervention and control groups. A utility score of 1.0 represents full health.  
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DISCUSSION 
We report a large randomised feasibility study of a specific physiotherapy-based treatment 
for FMS. Recruitment rate, enrolment and retention were high and clinical outcomes were 
promising, providing evidence that an appropriately powered RCT is feasible, timely and 
important. Thirty-two per cent of new patients presenting to our clinics with FMS met the 
selection criteria and there was a 90% enrolment rate. Given the high prevalence of such 
patients in general neurology clinics it follows that there are sufficient patients to run a larger 
version of this trial.[1,2] High rates of recruitment and retention point to the intervention 
being acceptable, supported by participant feedback forms. 
An important aim was to test the utility of a range of outcome measures and determine 
which to use in a power calculation for a future clinical trial. Measuring outcome in FMS is 
complicated by the variable nature of symptom severity inherent to the diagnosis. For this 
reason, snapshot measures of disability are likely to have problems with test-retest 
reliability, limiting their usefulness. Gait and balance outcome measures are restrictive as 
they are not applicable to patients with upper limb symptoms only. The SF36 Physical 
Function domain was the most promising primary outcome. It had a medium to large effect 
size (d=0.70), and it is not as vulnerable to symptom fluctuation, as answers are given based 
on the respondent’s perception of the average experience within the set recall period. 
There were no reported serious adverse incidents during the trial period. We did not identify 
any mental health related adverse events associated with physiotherapy treatment. Patients 
with clinically evident anxiety and depression warranting intervention were excluded from 
the study and referred to more appropriate treatment. Measures of mental health did not 
change in either group. Some participants in the intervention group reported an 
exacerbation of chronic fatigue related to the intensity of treatment, which resolved 
spontaneously over several days. We suspect the relatively high intensity and short duration 
is an important therapeutic element of our intervention, allowing gains made in therapy to 
be built upon in subsequent sessions, minimising time for symptom relapse or interference 
from environmental symptom maintaining factors. This intensity may make it unsuitable for 
some patients and with this in mind we excluded those for whom chronic pain or fatigue was 
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the dominant problem. Despite this, half the enrolled participants still rated their pain and 
fatigue as severe to extreme.  
To our knowledge, this is the first reported randomised study of physical rehabilitation for 
FMS with a control period greater than four weeks. With the caveat that this research was 
primarily designed to assess feasibility, we report a moderate to large treatment effect size 
across a range of measures of physical function, controlled over a six month period. A larger 
proportion of the intervention group rated their symptoms as improved (72%) compared to 
the control group (18%), while 32% of the control group felt their symptoms had worsened 
over the follow up period, compared to 3% in the intervention group. The effect size of the 
intervention is consistent with those of similar published studies in FMS, including our cohort 
study of 47 patients during the development phase of the five day programme;[8] a five day 
physiotherapy and occupational therapy based intervention;[26] and a randomised delayed-
start trial of a three week inpatient physical based rehabilitation programme.[5] The 
improvement reported in the current study occurred in a sample of patients with 
characteristics usually associated with a poor prognosis. The average FMS duration was 5·8 
years (SD 7·3), participants had multiple coexisting symptoms, and high rates of 
unemployment due to ill health. It is possible that if the intervention occurred earlier in the 
course of their disorder, it may have been more effective. 
The B-IPQ total score is thought to represent the threat value of an illness. In our study, the 
intervention was associated with a reduction in the B-IPQ total score in the intervention 
group and there was little change in the control group (table 2). We hypothesise that the 
intervention helped patients to understand their symptoms and improve control over their 
movement, both of which resulted in diminished concern. This may represent one 
mechanism by which the intervention affects change, although we recognise that the total B-
IPQ score may have problems with internal consistency.[27]  
The EQ-5D-5L is the preferred instrument for generating QALYs by the UK organisation the 
National Institute for Health and Care Excellence (NICE). The average difference in QALYs 
between the groups adjusting for baseline differences was 0.08 QALYs and the resulting ICER 
of £12,087 suggests the intervention is most likely cost effective. In general, an ICER below 
£20,000 is considered cost effective.[28] This is without accounting for a potential reduction 
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in the costs of health and social care utilisation, reduction in disability benefits and return to 
paid employment.  
We recognise a number of limitations in our study. It was not specifically designed or 
powered to detect a treatment effect. However, given the absence of controlled trials in the 
literature we considered reporting outcome appropriate. At baseline, the control group had 
scores that represented worse health than the intervention group. Our analysis accounted 
for baseline differences and there was still a large treatment effect with the intervention and 
little or no change with the control condition. A future trial could consider a randomisation 
procedure that involved minimisation to account for baseline severity. Participants and 
assessors were not masked to treatment allocation, which may have introduced bias. Most 
outcomes were subjective patient reported outcomes, which may be influenced by many 
factors, including the lack of blinding. We did not use a standardised diagnostic schedule to 
ascertain clinically significant anxiety or depression as a basis for exclusion from the study. 
This may have led to exclusion of some patients who might have benefitted from the 
programme. The intervention included an additional consultation with the study neurologist 
that was not offered to the control group. This may have enhanced the therapeutic benefit of 
the intervention, limiting generalisability to services where this is unavailable. Finally we did 
not standardise the control condition. A strength of the study is that the selection criteria 
were relatively inclusive (we did not exclude on the basis of age, FMS duration, or 
phenomenology), making results more transferable to a real world clinical context. 
In summary, this study demonstrates the feasibility of performing a large trial of specialist 
physiotherapy for FMS. We report a large treatment effect and evidence of cost benefit in a 
group of patients that are prevalent, have poor quality of life and have a poor prognosis with 
the current available treatment. The study data strongly support the need for a multicentre 
randomised trial of this intervention.  
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